Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

What biomarkers do we have for MND?

Original source

What biomarkers do we have for MND?Motor Neurone Disease Association (UK) · 8 July 2025 (opens in a new tab)

Related topics

The Motor Neurone Disease Association has published an overview of biomarkers being investigated for motor neurone disease (MND). It describes neurofilament, RNA signatures and urinary p75 protein as research candidates for diagnosis, disease progression and clinical trials. None is presented as a definitive diagnostic test or established treatment guide.

Why this matters

Earlier or more precise biomarkers could eventually help distinguish MND from similar conditions, estimate how quickly it may progress and measure treatment effects in trials. The review describes potential uses, including monitoring people with genetic risk, but it does not show that these approaches are ready for routine care or that they change treatment now.

Limitations and context

This is an organisational educational blog, not a primary research study or clinical guideline. It summarises ongoing research and says neurofilament is not specific to MND and that researchers are still confirming which form is most useful. The biomarkers discussed would still need validation in clinical studies before routine use.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?